中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 4
Apr.  2021
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(4): 813-816

Correlation of quality of life with aspartate aminotransferase-to-platelet ratio index, liver stiffness measurement, and histopathology after antiviral therapy for chronic hepatitis B liver fibrosis

DOI: 10.3969/j.issn.1001-5256.2021.04.018
  • a.

    Department of Pathology, The Affiliated Hospital of Yanbian University, Yanji, Jilin 133000, China

  • b.

    Department of Infectious Diseases, The Affiliated Hospital of Yanbian University, Yanji, Jilin 133000, China

  • Received Date: 2020-10-16
  • Accepted Date: 2020-12-26
  • Published Date: 2021-04-20
    Abstract
  •   Objective  To investigate the correlation of quality of life (QOL) with aspartate aminotransferase-to-platelet ratio index (APRI), liver stiffness measurement (LSM), and histopathology after entecavir antiviral therapy for patients with chronic hepatitis B liver fibrosis.  Methods  A total of 95 patients who were diagnosed with chronic hepatitis B and liver fibrosis in The Affiliated Hospital of Yanbian University from October 2013 to March 2015 were enrolled, and all patients underwent entecavir antiviral therapy. Before treatment and at weeks 26, 52, and 78 of treatment, SF-36 scale was used to assess QOL, transient elastography was used to measure LSM, and serum APRI was measured. Among these patients, 31 underwent liver biopsy before treatment and at week 78 of treatment to observe the degree of inflammation and fibrosis, and QOL, APRI, LSM, and histopathology were analyzed before and after antiviral therapy. The Kruskal-Wallis H test was used for comparison of non-normally distributed continuous data at different time points, and a Spearman correlation analysis was performed.  Results  There was a tendency of increase in QOL after antiviral treatment, and there were significant differences in general health, role-physical, role-motional, bodily pain, social functioning, and vitality at different time points (H=25.084, 8.699, 12.293, 22.874, 12.079, and 10.403, all P < 0.05). There was a tendency of reduction in APRI, with a significant change after treatment (H=60.030, P < 0.01), and there was also a significant reduction in LSM after treatment (H=35.744, P < 0.01). APRI and LSM were negatively correlated with QOL (all P < 0.05). Among the patients who underwent liver biopsy, 22 achieved the improvement in histological inflammation after antiviral therapy, 15 achieved the improvement in fibrosis, 14 achieved the improvement in both inflammation and QOL, and 8 achieved the improvement in both fibrosis and QOL.  Conclusion  Entecavir antiviral therapy can improve the QOL of patients with chronic hepatitis B liver fibrosis, and reductions in APRI and LSM can predict the improvement in QOL in patients with chronic hepatitis B liver fibrosis. Improvement in histological inflammation and fibrosis have a certain effect on the improvement in QOL in patients with chronic hepatitis B liver fibrosis.

     

    • FullText(HTML)
  • loading
    • References(17)
  • [1]
    ZHANG L, ZHANG J, ZHOU G, et al. SF-36 scale to evaluate the improvement of quality of life in HBeAg positive patients with chronic hepatitis B treated with antiviral therapy[J]. Chongqing Med, 2017, 46(32): 4582-4584. DOI: 10.3969/j.issn.1671-8348.2017.32.037.

    张林, 张婧, 周钢, 等. SF-36量表评价HBeAg阳性慢性乙型肝炎患者抗病毒治疗对生活质量的改善[J]. 重庆医学, 2017, 46(32): 4582-4584. DOI: 10.3969/j.issn.1671-8348.2017.32.037.
    [2]
    Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B: A 2015 update[J]. J Clin Hepatol, 2015, 31(12): 1941-1960. DOI: 10.3969/j.issn.1001-5256.2015.12.002.

    中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015年更新版)[J]. 临床肝胆病杂志, 2015, 31(12): 1941-1960. DOI: 10.3969/j.issn.1001-5256.2015.12.002.
    [3]
    ZHANG LX, ZHANG H, ZHANG W. Effect of comprehensive intervention program on quality of life of patients with chronic hepatitis B[J]. Guangdong Med J, 2014, 35(19): 3122-3124.

    张利霞, 张会, 张苇. 综合干预方案对慢性乙型肝炎患者生活质量的影响[J]. 广东医学, 2014, 35(19): 3122-3124.
    [4]
    LI HJ, HE JS, HU SL, et al. Clinical effficacy of acoustic radiation force pulse imaging、transient elastography、aspartate aminotransferase to platelet ratio index in the detection of liver fibrosis degree of hepatitis B[J]. Clin J Med Offic, 2020, 48(9): 1090-1091, 1094. DOI: 10.16680/j.1671-3826.2020.09.35.

    栗红江, 何久胜, 胡素玲, 等. 声辐射力脉冲成像技术、瞬时弹性成像技术及天冬氨酸氨基转移酶与血小板比率指数联合检测乙型肝炎肝纤维化程度临床效能[J]. 临床军医杂志, 2020, 48(9): 1090-1091, 1094. DOI: 10.16680/j.1671-3826.2020.09.35.
    [5]
    ZHENG SQ, WANG QZ. Current status and prospects of research on noninvasive diagnosis of liver fibrosis[J]. J Clin Hepatol, 2019, 35(1): 197-200. DOI: 10.3969/j.issn.1001-5256.2019.01.043.

    郑少秋, 王启之. 无创肝纤维化诊断研究现状与前景[J]. 临床肝胆病杂志, 2019, 35(1): 197-200. DOI: 10.3969/j.issn.1001-5256.2019.01.043.
    [6]
    WU FX, GAO BH, NIU CY, et al. Value of aspartate aminotransferase -to-platelet ratio index in diagnosis and prediction of liver fibrosis degree in patients with chronic hepatitis B[J]. J Clin Hepatol, 2017, 33(8): 1483 -1486. DOI: 10.3969/j.issn.1001-5256.2017.08.014

    吴方雄, 高保华, 牛春燕, 等. APRI评分对慢性乙型肝炎肝纤维化程度的诊断及预测价值[J]. 临床肝胆病杂志, 2017, 33(8): 1483-1486. DOI: 10.3969/j.issn.1001-5256.2017.08.014
    [7]
    AFIFY SM, TABLL A, NAWARA HM, et al. Five fibrosis biomarkers together with serum ferritin level to diagnose liver fibrosis and cirrhosis[J]. Clin Lab, 2018, 64(10): 1685-1693. DOI: 10.7754/Clin.Lab.2018.180502.
    [8]
    KEMP W, LEVY M, WELTMAN M, et al. Australian Liver Association (ALA) expert consensus recommendations for the use of transient elastography in chronic viral hepatitis[J]. J Gastroenterol Hepatol, 2015, 30(3): 453-462. DOI: 10.1111/jgh.12865.
    [9]
    ŞAHIN A, NAM|DURU M, BALKAN A, et al. Assessment of histopathological alterations in patients with chronic hepatitis B infection following long-term oral antiviral therapy[J]. Saudi Med J, 2018, 39(10): 999-1005. DOI: 10.15537/smj.2018.10.23056.
    [10]
    SUN Y, ZHOU J, WANG L, et al. New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment[J]. Hepatology, 2017, 65(5): 1438-1450. DOI: 10.1002/hep.29009.
    [11]
    Chinese Society of Infectious Diseases and Parasitology, Chinese Society of Hepatology, Chinese Medical Association. Prevention and treatment of viral hepatitis[J]. Chin J Infect Dis, 2001, 19(1): 56-62. DOI: 10.3760/j.issn:1000-6680.2001.01.027.

    中华医学会传染病与寄生虫病学分会、肝病学分会. 病毒性肝炎防治方案[J]. 中华传染病杂志, 2001, 19(1): 56-62. DOI: 10.3760/j.issn:1000-6680.2001.01.027.
    [12]
    WONG CK, LAM ET, LAM CL. Comparison of direct-measured and derived short form six dimensions (SF-6D) health preference values among chronic hepatitis B patients[J]. Qual Life Res, 2013, 22(10): 2973-2981. DOI: 10.1007/s11136-013-0403-z.
    [13]
    WARE J, GANDEK B. Overview of SF-36 health survy and the international quality of life assessment (IQOLA) project[J]. J Clin Epidemiol, 1998, 51(11): 903-912. DOI: 10.1016/s0895-4356(98)00081-x.
    [14]
    XUE X, CAI S, OU H, et al. Health-related quality of life in patients with chronic hepatitis B during antiviral treatment and off-treatment[J]. Patient Prefer Adherence, 2017, 11: 85-93. DOI: 10.2147/PPA.S127139.
    [15]
    ZHOU H, XU QX, ZHANG ZG, et al. Clinical efficacy and quality of life evaluation of entecavir in patients with chronic hepatitis B[J]. Chin J Integr Tradit West Med Liver Dis, 2013, 23(6): 324-327.

    周虹, 徐秋仙, 张振纲, 等. 恩替卡韦治疗慢性乙型肝炎患者的临床疗效及其生存质量评价[J]. 中西医结合肝病杂志, 2013, 23(6): 324-327.
    [16]
    Consensus expert committee on clinical application of transient elastography (TE). Consensus expert on clinical application of transient elastography (TE) (2015)[J/CD]. Chin J Hepatol(Electronic Edition), 2015, 7(2): 12-18. DOI: 10.3969/j.issn.1674-7380.2015.02.002.

    瞬时弹性成像技术(TE)临床应用共识专家委员会. 瞬时弹性成像技术(TE)临床应用专家共识(2015年)[J/CD]. 中国肝脏病杂志(电子版), 2015, 7(2): 12-18. DOI: 10.3969/j.issn.1674-7380.2015.02.002.
    [17]
    SUN Y, ZHOU J, WANG L, et al. New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment[J]. Hepatology, 2017, 65(5): 1438-1450. DOI: 10.1002/hep.29009.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (521) PDF downloads(67) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return